TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases
Gene signatures, such as <i>TP53</i> or <i>EGFR</i> amplification, were associated with worse survival in patients diagnosed with NSCLC-BM. These valuable findings may shed light on new strategies for the prognostic assessment of specific patient groups.
Authors
- Linbo Cai (ORCID: https://orcid.org/0000-0003-4411-4125)
- Da Liu (ORCID: https://orcid.org/0000-0002-5113-4004)
- Weiping Hong (ORCID: https://orcid.org/0009-0009-9856-5854)
- Min-Ying Li (ORCID: https://orcid.org/0000-0002-2075-6636)
- Lin Tao (ORCID: https://orcid.org/0000-0001-7494-4758)
- Yongqin Zeng
- Lei Wen (ORCID: https://orcid.org/0000-0002-3461-6060)
- Zhijie Chen (ORCID: https://orcid.org/0000-0001-9232-7382)
- Hainan Yang (ORCID: https://orcid.org/0000-0001-6864-1478)
- Zhaoming Zhou (ORCID: https://orcid.org/0000-0002-9788-0184)
- Minting Ye
- Xusheng Tang
- Wanli Yang
Institutions
- Tongji University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Zhongshan People's Hospital (CN)
- Zhujiang Hospital (CN)
- Seventh People's Hospital of Shanghai (CN)
- Guangdong 999 Brain Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e36532
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00